On Could 15, 2026, Exome Asset Administration reported promoting out of Wave Life Sciences (NASDAQ:WVE), liquidating 421,488 shares in an estimated $5.49 million commerce primarily based on quarterly common pricing.
What occurred
In line with an SEC submitting dated Could 15, 2026, Exome Asset Administration bought its total stake of 421,488 shares in Wave Life Sciences. The estimated worth of the transaction is $5.49 million, calculated utilizing the common closing worth through the first quarter of 2026. The quarter-end worth of Exome’s place within the firm dropped by $7.17 million, a determine that features each buying and selling exercise and worth fluctuations.
What else to know
-
Exome Asset Administration LLC absolutely exited its Wave Life Sciences place, which was beforehand 3.4% of the fund’s AUM.
-
High holdings after the submitting:
-
NASDAQ: PRAX: $14.65 million (8.6% of AUM)
-
NASDAQ: COGT: $10.72 million (6.3% of AUM)
-
NASDAQ: ELVN: $8.63 million (5.1% of AUM)
-
NASDAQ: IONS: $8.26 million (4.9% of AUM)
-
NASDAQ: GH: $7.64 million (4.5% of AUM)
-
-
As of Could 14, 2026, shares of Wave Life Sciences had been priced at $6.90, up 8% over the previous 12 months, underperforming the S&P 500 by almost 20 share factors.
Firm overview
|
Metric |
Worth |
|---|---|
|
Worth (as of market shut Could 14, 2026) |
$6.90 |
|
Market capitalization |
$1.33 billion |
|
Income (TTM) |
$71.80 million |
|
Web revenue (TTM) |
($183.59 million) |
Firm snapshot
-
Wave Life Sciences develops stereopure oligonucleotide therapies focusing on neurological, hepatic, and genetic issues, with scientific candidates together with WVE-004 (ALS/FTD), WVE-003 (Huntington’s illness), and WVE-N531 (Duchenne muscular dystrophy).
-
The agency operates a clinical-stage biotechnology enterprise mannequin centered on proprietary drug discovery and improvement, leveraging its PRISM platform and strategic collaborations to advance a pipeline of RNA-targeted medicines.
-
It serves pharmaceutical companions, analysis establishments, and sufferers with uncommon and severe genetic illnesses, primarily in neurology and hepatology.
Wave Life Sciences is a clinical-stage biotechnology firm specializing within the design and improvement of stereopure oligonucleotide therapeutics. It leverages its proprietary PRISM platform and strategic partnerships to advance a diversified pipeline focusing on neurological and hepatic indications. The corporate’s deal with precision genetic medicines positions it to handle unmet medical wants in uncommon and complicated illnesses, supported by collaborations with main world pharmaceutical and educational companions.
What this transaction means for buyers
The efficiency of early-stage biotechs is extremely contingent on scientific execution, that means funding outcomes can hinge on a handful of knowledge releases and regulatory choices moderately than regular working efficiency. That’s notable right here as a result of Wave shares took a large tumble in late March, collapsing roughly 50% in sooner or later after new information confirmed {that a} greater dose of its weight problems candidate, WVE-007, failed to indicate significant enchancment in lowering a kind of stomach fats.
However, the agency appeared optimistic in its newest earnings launch. CEO Paul Bolno stated the corporate is “accelerating” improvement of WVE-007 following encouraging early physique composition information and stays on monitor throughout a number of pipeline applications. Financially, Wave generated $38.2 million in first-quarter income, up from $9.2 million a 12 months earlier, whereas narrowing its web loss to $26.1 million from $46.9 million. It ended March with $544.6 million in money and expects that funding to final into the third quarter of 2028.
Finally, this stays a pipeline story, and Exome’s exit could mirror danger administration, however the subsequent significant driver of returns will possible be scientific and regulatory execution moderately than institutional buying and selling exercise.
